Immune Therapy for Prostate Cancer.
Immune Therapy for Prostate Cancer.
复制标题
DOI：
10.1097/ppo.0000000000000223
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Slovin SF
中科院分区：
文献类型：
--
作者：
Yeku O;Slovin SF
去势抵抗性前列腺癌的免疫治疗在过去几年中一直是一个活跃的研究领域。这种方法的热情是基于更好的耐受性的假设，并且使用人体自身的免疫系统可能比激素或化疗更有效。Sipuleucel-T是一种基于树突状细胞的疫苗，是该类药物中唯一获批用于治疗去势抵抗性前列腺癌的药物。虽然Sipuleucel-T增加了总生存期，但无进展生存期没有任何显著变化，但其他形式的免疫疗法，如PSA-TRICOM，Ipilimumab和CAR-T细胞疗法正处于临床开发的后期阶段。正在开发免疫生物标志物来评估对这些治疗的反应，并了解免疫系统如何对这些相应的治疗作出反应。免疫疗法与雄激素剥夺、放射疗法和化学疗法的组合也已被探索，具有不同的结果。本文综述了免疫抑制剂治疗去势抵抗性前列腺癌的机制、关键临床前和临床数据以及前景。
Immunotherapy for castration resistant prostate cancer has continued to be an area of active research over the last several years. The enthusiasm of this approach has been based on the assumption of better tolerability and that using the body’s own immune system may be more effective than either hormonal or chemotherapy. Sipuleucel-T, a dendritic cell based vaccine is the only approved agent in this class for the management of castrate resistant prostate cancer. Although Sipuleucel-T increases overall survival without any significant changes in progression free survival, other forms of immunotherapy such as PSA-TRICOM, Ipilimumab and CAR-T cell therapy are in advanced stages of clinical development. Immune biomarkers are being developed to assess response to these treatments and also to understand how the immune system responds to these respective therapies. Combinations of immunotherapy with androgen deprivation, radiation therapy, and chemotherapy have also been explored with varying results. This review discusses the mechanisms, key preclinical and clinical data, and perspectives for immunotherapeutic agents in the treatment scheme for castrate resistant prostate cancer.